GSK's RSV vaccine shows positive results in adults aged 50-59
The British drugmaker's shot, called Arexvy, met the primary goal in the Phase-III trial of eliciting an immune response in adults of the reported age group who are at an increased risk of catching the virus due to certain underlying medical conditions, the company said on Wednesday. RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.